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I drive two cars and usually wear a seat-
belt. In my older car, I sometimes forget
to buckle up. In the newer model, I never
fail to perform this task—an alarm pesters
me until the deed is done. Today, we have
finally identified protective measures,
including early testing and treatment and
mother-child chemoprophylaxis, that
could usher in an AIDS-free generation.
But to truly arrest its spread, these tools
must transition from research into
everydaypractice, a challenge that cannot
be overestimated. And as with seat belts,
the effort will succeed only if these mea-
sures are applied widely and consistently.
Five elements will be required: (1) a
louder and continued clarion call mobi-
lizing the public and the political leader-
ship; (2) global champions with fiscal
resources supporting the effort; (3)
adequate public health infrastructure
and capacity; (4) public-private partner-
ships to maximize the resources and
approaches; and (5) sustained scientific
investment into more effective solutions.
Do we have the requisite political will,
economic resources, diagnostic technol-
ogy, manufacturing capacity, clinical
infrastructure, and healthcare delivery
systems to ensure that these measures
are applied reproducibly, systematically,
and with local flexibility? The US
Government initiative PEPFAR markedly
advanced global drug treatment, and calls
formore comprehensive action have been
issued. Yet progress has been alarmingly
slow. The need for systems to apply these
new interventions in everyday life remains
urgent.
A seat belt not used saves no lives.Defining Protective Antibodies
Nancy L. Haigwood
Oregon National Primate Research Center
My hopes for achieving an AIDS-free
world rest on the eventual development
of an effective prophylactic vaccine. Until
then, research focused on defining the
complexity of a protective antibody
response and applying that knowledge
to develop therapeutics could slow the
pandemic and save lives. Primate experi-
ments and the modestly successful
human RV144 vaccine trial predict that
prevention of HIV infection requires anti-
bodies. Unfortunately, current vaccines
cannot yet elicit a response of sufficient
potency and breadth, and a vaccine that
fails to block infection must rapidly induce
immune responses that are ‘‘inescap-
able.’’ Advances in antibody discovery
have led to a collection of powerful human
HIV-neutralizing antibodies. Now, a per-
fect opportunity exists to use these anti-
bodies to determine what will be needed
to prevent, control, and potentially clear
HIV infection in humans. We know that
neutralizing antibodies not only block
infection in primate models, but also
remarkably, if given within 24 hours of
virus exposure, can permanently improve
the course of infection and enhance
adaptive immune responses. If antibodies
were to have these same effects in
humans, this would represent a sea
change in treatment avenues for HIV
infection. Antibodies are safe, easy to pro-
duce, and could be engineered for gene
therapy. Investing in antibody therapeutic
studies is warranted because their results
could ultimately define the potency,
complexity, and determinants of the best
combinations of antibodies needed in
effective vaccines.Cell 155Beyond the ‘‘Berlin Patient’’
Timothy J. Henrich
Brigham and Women’s Hospital, Harvard Medical
School
Since the world learned of the ‘‘Berlin
Patient’’ 5 years ago, there has been
tremendous excitement in both the scien-
tific and lay communities about the poten-
tial for an HIV ‘‘cure.’’ Much has been
learned about where and how HIV per-
sists, and a number of provocative
studies have demonstrated the potential
for antiretroviral therapy to prevent new
infections or, when used very early after
acquisition, to lead to antiretroviral-free
control. Modalities are being developed
to alter host cell susceptibility to infection,
and allergenic stem cell transplantation
has been shown to reduce the size of
latent HIV reservoirs. The idea of an
AIDS-free world has gone from pipe
dream to potential reality. Yet these
exciting observations remain proof of
concept, and more scalable strategies,
such as activating and purging latent res-
ervoirs, have not yet been shown to have
a durable impact on HIV persistence. The
true measure of success in achieving an
AIDS-free world is the development of
curative strategies that are safe, afford-
able, and scalable to the >34 million peo-
ple living with HIV world-wide. Prevention
alone will not make an AIDS-free world a
reality in the coming decades. We are
not there yet and likely have a long and
difficult road ahead. We will need ongoing
economic and scientific investment to
continue the momentum gained over the
past several years and to relegate AIDS
to the history books., October 24, 2013 ª2013 Elsevier Inc. 491
Two Paths to a Cure
Michel C. Nussenzweig
Rockefeller University
There are only two ways to achieve an
AIDS-free world: finding a cure or devel-
oping a vaccine. Although combination
antiretroviral therapy controls HIV replica-
tion and prevents AIDS in infected individ-
uals, it fails to eliminate silent viral reser-
voirs in latently infected cells. The key to
a cure is destroying these persistent res-
ervoirs. However, progress has been
slow, in part because there are no rapid
techniques to identify, purify, study, or
target these rare cells. New therapeutic
modalities such as antibodies that clear
the virus and infected cells, as well as
agents activating the latent reservoir,
should be explored. A vaccine to HIV
has also been elusive, but recent discov-
eries have renewed optimism. First, the
RV144 human vaccine trial showed
modest levels of protection, correlated
with antibody responses. Second, newly
developed single-cell antibody cloning
methods uncovered the existence of
naturally occurring neutralizing antibodies
that can prevent infection at low concen-
trations. These antibodies have unusual
features such as very high levels of
somatic hypermutation and long comple-
mentarity determining regions, and they
tend to be polyreactive. How to elicit these
antibodies by immunization remains to be
determined, but now that we know that
humans can produce them and have
defined some of their properties, the
problem can be reduced to designing a
novel means of vaccination that repro-
duces a naturally occurring phenomenon.492 Cell 155, October 24, 2013 ª2013 ElseviNo Magic Bullet
Kevin Robert Frost
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Research advances in recent years have
given us real hope that we could bring
the AIDS pandemic under control. To
achieve this, we need to scale up those
interventions we know to be effective,
including HIV treatment, voluntary medi-
cal male circumcision, harm reduction,
prevention of mother-to-child transmis-
sion services, and condom access.
These interventions are proven to work
in countries with generalized epidemics.
And in countries where HIV is concen-
trated in populations such as gay men
and other men who have sex with men,
transgender individuals, injection drug
users, and sex workers, we need to focus
our efforts on these key groups. We need
to base our public health policies on evi-
dence-based interventions. Syringe ex-
change programs, for example, are highly
effective at reducing the spread of HIV
among IDUs, so let’s urge our policy
makers to put aside their ideological ob-
jections and invest in these services. We
also need to invest in the implementation
research that will help us effectively
deploy, and adapt where necessary,
those interventions that work best. We
likely won’t get close to an AIDS-free
world without a cure and a vaccine, so a
robust and sustained research effort is
essential in both of these areas. There’s
no magic bullet for AIDS, but if we find
the resources and the political will to do
all of these things, we might just see the
dawn of an AIDS-free future. Or some-
thing close to it.er Inc.
